Results 211 to 220 of about 20,756 (294)

Ten‐Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Biologic therapies are a major and growing driver of pharmaceutical expenditure globally, with tumor necrosis factor (TNF) inhibitors among the most widely used and costly biologics. In Australia, these therapies are funded through the Pharmaceutical Benefits Scheme (PBS), where biosimilars offer lower cost alternatives; however, the long‐term public ...
Chin Hang Yiu   +4 more
wiley   +1 more source

Digital Transformation of Medicines Regulation in Africa—Perspectives from a Stakeholder Convening

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Regulatory authorities worldwide are developing strategies to integrate artificial intelligence (AI) into the lifecycle of health products, technologies, and medicines. While regulators share goals of improving efficiency, strengthening decision‐making, and protecting public health, their approaches differ according to institutional structures ...
Christelna Reyneke   +12 more
wiley   +1 more source

From Custom to Court: The Evolution of Mediation in European Legal Systems

open access: yesConflict Resolution Quarterly, EarlyView.
ABSTRACT This article traces how European mediation has repeatedly rebalanced three variables—(1) the source of mediator authority, (2) the degree of institutionalization, and (3) the operative meaning of voluntariness—from antiquity to the present. Using three periods—Proto‐Mediation (c. 500 BCE–c. 1750), Classical Mediation (c.
Viktoriia Hamaiunova
wiley   +1 more source

“Efforts to Surface the Unspoken”: A Mixed Methods Study of a Risk‐Informed Check‐In in Norwegian Family Mediation

open access: yesConflict Resolution Quarterly, EarlyView.
ABSTRACT In family mediation, emotional discomfort and perceived unsafety may signal deeper relational risks, including postseparation violence. Standard intake procedures in Norwegian family mediation depend on disclosure to a nonclinical administrator before any therapeutic relationship exists, and research documents systematic under‐reporting at ...
Jan Stokkebekk   +2 more
wiley   +1 more source

Tokenism or Catalytic? Exploring Board Gender Diversity Through the Lens of SDG 9 Outcomes in the EU Context

open access: yesCorporate Social Responsibility and Environmental Management, EarlyView.
ABSTRACT This study explores the relationship between Executive gender diversity (EGD) and the achievement of Sustainable Development Goal 9 (SDG 9—Industry, Innovation, and Infrastructure) in the European Union. It investigates whether female representation in corporate governance contributes to innovation‐driven sustainability.
Suzan Dsouza   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy